|
Gene: FAM169A |
Gene summary for FAM169A |
Gene summary. |
Gene information | Species | Human | Gene symbol | FAM169A | Gene ID | 26049 |
Gene name | family with sequence similarity 169 member A | |
Gene Alias | SLAP75 | |
Cytomap | 5q13.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9Y6X4 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
26049 | FAM169A | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.49e-02 | -6.07e-02 | -0.1869 |
26049 | FAM169A | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 3.01e-06 | -5.05e-02 | -0.1883 |
26049 | FAM169A | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 5.32e-03 | -7.79e-03 | -0.1917 |
26049 | FAM169A | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 7.26e-04 | 1.55e-02 | -0.1916 |
26049 | FAM169A | NAFLD1 | Human | Liver | NAFLD | 2.53e-03 | 3.85e-01 | -0.04 |
26049 | FAM169A | HCC1_Meng | Human | Liver | HCC | 3.68e-09 | 1.76e-02 | 0.0246 |
26049 | FAM169A | HCC1 | Human | Liver | HCC | 8.00e-06 | 2.18e+00 | 0.5336 |
26049 | FAM169A | HCC2 | Human | Liver | HCC | 3.16e-04 | 3.03e+00 | 0.5341 |
26049 | FAM169A | HCC5 | Human | Liver | HCC | 2.64e-07 | 1.80e+00 | 0.4932 |
26049 | FAM169A | S014 | Human | Liver | HCC | 8.22e-07 | 2.89e-01 | 0.2254 |
26049 | FAM169A | S015 | Human | Liver | HCC | 1.42e-13 | 4.35e-01 | 0.2375 |
26049 | FAM169A | S016 | Human | Liver | HCC | 5.61e-15 | 3.70e-01 | 0.2243 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Endometrium | AEH: Atypical endometrial hyperplasia | |
EEC: Endometrioid Cancer | ||
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM169A | SNV | Missense_Mutation | novel | c.572G>T | p.Gly191Val | p.G191V | Q9Y6X4 | protein_coding | deleterious(0) | probably_damaging(0.976) | TCGA-MP-A4TI-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FAM169A | SNV | Missense_Mutation | c.736N>C | p.Gly246Arg | p.G246R | Q9Y6X4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-18-3414-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
FAM169A | SNV | Missense_Mutation | c.1208C>A | p.Ala403Glu | p.A403E | Q9Y6X4 | protein_coding | tolerated(0.71) | benign(0.037) | TCGA-37-5819-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD | |
FAM169A | SNV | Missense_Mutation | novel | c.589N>T | p.His197Tyr | p.H197Y | Q9Y6X4 | protein_coding | tolerated(1) | benign(0.253) | TCGA-58-8386-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
FAM169A | SNV | Missense_Mutation | c.143N>T | p.Ser48Ile | p.S48I | Q9Y6X4 | protein_coding | deleterious(0.02) | possibly_damaging(0.825) | TCGA-63-5128-01 | Lung | lung squamous cell carcinoma | Male | Unknown | I/II | Unknown | Unknown | PD | |
FAM169A | SNV | Missense_Mutation | novel | c.1129N>C | p.Glu377Gln | p.E377Q | Q9Y6X4 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-63-A5MH-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
FAM169A | SNV | Missense_Mutation | c.1769N>A | p.Ser590Tyr | p.S590Y | Q9Y6X4 | protein_coding | deleterious(0) | probably_damaging(0.988) | TCGA-77-6843-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
FAM169A | SNV | Missense_Mutation | c.413G>T | p.Cys138Phe | p.C138F | Q9Y6X4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-NC-A5HP-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
FAM169A | SNV | Missense_Mutation | novel | c.1153N>A | p.Glu385Lys | p.E385K | Q9Y6X4 | protein_coding | tolerated(0.1) | possibly_damaging(0.896) | TCGA-BA-5559-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
FAM169A | SNV | Missense_Mutation | c.461N>T | p.Ala154Val | p.A154V | Q9Y6X4 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BR-4362-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |